O-acetylcarnitine | 3040-38-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: O-acetylcarnitine
• 英文别名: [(2R)-2-acetyloxy-3-carboxypropyl]-trimethylazanium
• CAS: 3040-38-8
• 化学式: C9H18NO4+
• 分子量: 204.24
• InChiKey: RDHQFKQIGNGIED-MRVPVSSYSA-O

物化性质

• LogP：
  -4.031 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-acetylcarnitine 、 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one dihydrochloride 、 三乙胺 、 二氯甲烷 在 氯化亚砜 、 甲苯 、 二氯甲烷 、 Brine 、 乙腈 、 水 作用下， 以 氯化亚砜 为溶剂， 反应 21.0h， 以to give the required product (0.39 g)的产率得到3-(4-(4-((3R)-3-Acetoxy-4-trimethylammoniobutanoyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one chloride
  参考文献：
  名称：

  Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them

  摘要：

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，其中，例如，X为-O-或-S-; HET是一个含有2到4个杂原子（独立选择自N，O和S）的可选择取代的C-连接的5元杂芳基环; Q从Q1和Q2中选择，R2和R3独立地为氢或氟; T从一系列基团中选择，例如，一个N-连接（完全不饱和）的5元杂芳基环系统或公式（TC5）的基团：其中Rc是，例如，R13CO-，R13SO2-或R13CS-;其中R13是，例如，可选择取代的（1-10C）烷基或R14C（O）O（1-6C）烷基，其中R14是可选择取代的（1-10C）烷基;这些化合物可用作抗菌剂;并描述了其制造过程和含有它们的制药组合物。

  公开号：

  US20030144263A1

文献信息

• L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same
  申请人：Chen Jian

  公开号：US20100317890A1

  公开（公告）日：2010-12-16

  Salts of L-carnitine and alkanoyl L-carnitines with phytic acid of general formula (I), and the process of preparing the same, wherein the mole ratio between the L-carnitine or its alkanoyl derivatives cation and phytic acid anion be within the range of 1:1 to 6:1, wherein: n=1-6; R 1 is the phytate anion; R is either hydrogen, a straight alkanoyl group having 2-12 carbon atoms or a branched-chain alkanoyl group having 2-12 carbon atoms.

  L-肉碱盐和辛酰基L-肉碱盐与通式(I)的植酸，以及其制备方法，其中L-肉碱或其辛酰基衍生物阳离子与植酸阴离子之间的摩尔比在1:1至6:1的范围内，其中：n=1-6；R1是植酸阴离子；R是氢，具有2-12个碳原子的直链辛酰基或具有2-12个碳原子的支链辛酰基。
• OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：AstraZeneca UK Limited

  公开号：EP1082323A2

  公开（公告）日：2001-03-14
• Cleavable Carnitine Compound
  申请人：Singh Inder Pal

  公开号：US20090312404A1

  公开（公告）日：2009-12-17

  The invention includes novel compounds, including but not limited to formula A and formula B, and an improved delivery method. These compounds and methods are useful in preventing or treating diseases or conditions associated with or caused by the presence of free radicals, and are useful for increasing cellular metabolism while simultaneously alleviating the resultant increase in oxidative stress. Specifically, a carnitine is bound to a lipoic acid derivative or to dihydrolipoic acid or its derivatives using a hydrolysable linker to form a single compound.
• MULTIPARTICULATE L-CARNITINE COMPOSITIONS AND RELATED METHODS
  申请人：SHAH Syed

  公开号：US20120315326A1

  公开（公告）日：2012-12-13

  Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.
• Multiparticulate L-Carnitine Compositions and Related Methods
  申请人：Zx Pharma, LLC

  公开号：US20140370112A1

  公开（公告）日：2014-12-18

  An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.